A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab

Aruna Mani, Julie Roda, Donn Young, Michael A. Caligiuri, Gini F. Fleming, Peter Kaufman, Adam Brufsky, Susan Ottman, William E. Carson, Charles L. Shapiro

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Trastuzumab mediates the lysis of HER2-expressing breast cancer cell lines by interleukin-2 (IL-2) primed natural killer (NK) cells. We hypothesized that IL-2 would augment the anti-tumor effects of trastuzumab in MBC in patients who had progressed on or within 12 months of receiving a trastuzumab-containing regimen. Secondary objectives were to measure antibody-directed cellular cytotoxicity (ADCC) against HER2 over-expressing target cells, and to measure serum cytokines. Patients received trastuzumab (4 mg/kg intravenously (IV)) every 2 weeks in combination with daily low-dose IL-2 (1 million IU/m 2 subcutaneously (SC)) and pulsed intermediate-dose IL-2 (12 million IU/m2 SC). Samples were analyzed for NK cell expansion and ADCC against a HER2-positive breast cancer cell line. In addition, interferon-gamma (IFN-γ), mRNA expression in peripheral blood mononuclear cells (PBMC) and the following serum cytokines were measured: IFN-γ, monokine-induced by IFN-γ (MIG), and interferon-inducible protein ten (IP-10). The median number of treatment cycles was four (range 1-23) and the treatment was well tolerated. There were no objective responses. NK cells were not expanded and ADCC was not enhanced. Eight (62%) patients had a twofold or higher increase in mRNA transcript for IFN-γ, two (15%) patients had elevated serum levels of IFN-γ and 12 (92%) had increases angiogenic MIG and IP-10. In trastuzumab-refractory patients adding IL-2 did not produce responses and did not result in NK cell expansion. However, these patients had the ability to respond to IL-2 as evidenced by increases in IFN-γ transcripts and chemokines. The lack of NK cell expansion may explain the absence of clinical benefit.

Original languageEnglish (US)
Pages (from-to)83-89
Number of pages7
JournalBreast Cancer Research and Treatment
Volume117
Issue number1
DOIs
StatePublished - Sep 2009
Externally publishedYes

Fingerprint

Interferon-gamma
Interleukin-2
Breast Neoplasms
Natural Killer Cells
Antibodies
C Chemokines
Serum
Monokines
Cytokines
Cell Line
Messenger RNA
Interleukin-12
Trastuzumab
Interleukin-1
Blood Cells
Therapeutics
Neoplasms
Proteins

Keywords

  • Breast cancer
  • Clinical trial
  • Her-2/neu
  • Interleukin-2
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. / Mani, Aruna; Roda, Julie; Young, Donn; Caligiuri, Michael A.; Fleming, Gini F.; Kaufman, Peter; Brufsky, Adam; Ottman, Susan; Carson, William E.; Shapiro, Charles L.

In: Breast Cancer Research and Treatment, Vol. 117, No. 1, 09.2009, p. 83-89.

Research output: Contribution to journalArticle

Mani, Aruna ; Roda, Julie ; Young, Donn ; Caligiuri, Michael A. ; Fleming, Gini F. ; Kaufman, Peter ; Brufsky, Adam ; Ottman, Susan ; Carson, William E. ; Shapiro, Charles L. / A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. In: Breast Cancer Research and Treatment. 2009 ; Vol. 117, No. 1. pp. 83-89.
@article{090a8d4127f34093b63d387455b5914c,
title = "A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab",
abstract = "Trastuzumab mediates the lysis of HER2-expressing breast cancer cell lines by interleukin-2 (IL-2) primed natural killer (NK) cells. We hypothesized that IL-2 would augment the anti-tumor effects of trastuzumab in MBC in patients who had progressed on or within 12 months of receiving a trastuzumab-containing regimen. Secondary objectives were to measure antibody-directed cellular cytotoxicity (ADCC) against HER2 over-expressing target cells, and to measure serum cytokines. Patients received trastuzumab (4 mg/kg intravenously (IV)) every 2 weeks in combination with daily low-dose IL-2 (1 million IU/m 2 subcutaneously (SC)) and pulsed intermediate-dose IL-2 (12 million IU/m2 SC). Samples were analyzed for NK cell expansion and ADCC against a HER2-positive breast cancer cell line. In addition, interferon-gamma (IFN-γ), mRNA expression in peripheral blood mononuclear cells (PBMC) and the following serum cytokines were measured: IFN-γ, monokine-induced by IFN-γ (MIG), and interferon-inducible protein ten (IP-10). The median number of treatment cycles was four (range 1-23) and the treatment was well tolerated. There were no objective responses. NK cells were not expanded and ADCC was not enhanced. Eight (62{\%}) patients had a twofold or higher increase in mRNA transcript for IFN-γ, two (15{\%}) patients had elevated serum levels of IFN-γ and 12 (92{\%}) had increases angiogenic MIG and IP-10. In trastuzumab-refractory patients adding IL-2 did not produce responses and did not result in NK cell expansion. However, these patients had the ability to respond to IL-2 as evidenced by increases in IFN-γ transcripts and chemokines. The lack of NK cell expansion may explain the absence of clinical benefit.",
keywords = "Breast cancer, Clinical trial, Her-2/neu, Interleukin-2, Trastuzumab",
author = "Aruna Mani and Julie Roda and Donn Young and Caligiuri, {Michael A.} and Fleming, {Gini F.} and Peter Kaufman and Adam Brufsky and Susan Ottman and Carson, {William E.} and Shapiro, {Charles L.}",
year = "2009",
month = "9",
doi = "10.1007/s10549-008-0251-7",
language = "English (US)",
volume = "117",
pages = "83--89",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab

AU - Mani, Aruna

AU - Roda, Julie

AU - Young, Donn

AU - Caligiuri, Michael A.

AU - Fleming, Gini F.

AU - Kaufman, Peter

AU - Brufsky, Adam

AU - Ottman, Susan

AU - Carson, William E.

AU - Shapiro, Charles L.

PY - 2009/9

Y1 - 2009/9

N2 - Trastuzumab mediates the lysis of HER2-expressing breast cancer cell lines by interleukin-2 (IL-2) primed natural killer (NK) cells. We hypothesized that IL-2 would augment the anti-tumor effects of trastuzumab in MBC in patients who had progressed on or within 12 months of receiving a trastuzumab-containing regimen. Secondary objectives were to measure antibody-directed cellular cytotoxicity (ADCC) against HER2 over-expressing target cells, and to measure serum cytokines. Patients received trastuzumab (4 mg/kg intravenously (IV)) every 2 weeks in combination with daily low-dose IL-2 (1 million IU/m 2 subcutaneously (SC)) and pulsed intermediate-dose IL-2 (12 million IU/m2 SC). Samples were analyzed for NK cell expansion and ADCC against a HER2-positive breast cancer cell line. In addition, interferon-gamma (IFN-γ), mRNA expression in peripheral blood mononuclear cells (PBMC) and the following serum cytokines were measured: IFN-γ, monokine-induced by IFN-γ (MIG), and interferon-inducible protein ten (IP-10). The median number of treatment cycles was four (range 1-23) and the treatment was well tolerated. There were no objective responses. NK cells were not expanded and ADCC was not enhanced. Eight (62%) patients had a twofold or higher increase in mRNA transcript for IFN-γ, two (15%) patients had elevated serum levels of IFN-γ and 12 (92%) had increases angiogenic MIG and IP-10. In trastuzumab-refractory patients adding IL-2 did not produce responses and did not result in NK cell expansion. However, these patients had the ability to respond to IL-2 as evidenced by increases in IFN-γ transcripts and chemokines. The lack of NK cell expansion may explain the absence of clinical benefit.

AB - Trastuzumab mediates the lysis of HER2-expressing breast cancer cell lines by interleukin-2 (IL-2) primed natural killer (NK) cells. We hypothesized that IL-2 would augment the anti-tumor effects of trastuzumab in MBC in patients who had progressed on or within 12 months of receiving a trastuzumab-containing regimen. Secondary objectives were to measure antibody-directed cellular cytotoxicity (ADCC) against HER2 over-expressing target cells, and to measure serum cytokines. Patients received trastuzumab (4 mg/kg intravenously (IV)) every 2 weeks in combination with daily low-dose IL-2 (1 million IU/m 2 subcutaneously (SC)) and pulsed intermediate-dose IL-2 (12 million IU/m2 SC). Samples were analyzed for NK cell expansion and ADCC against a HER2-positive breast cancer cell line. In addition, interferon-gamma (IFN-γ), mRNA expression in peripheral blood mononuclear cells (PBMC) and the following serum cytokines were measured: IFN-γ, monokine-induced by IFN-γ (MIG), and interferon-inducible protein ten (IP-10). The median number of treatment cycles was four (range 1-23) and the treatment was well tolerated. There were no objective responses. NK cells were not expanded and ADCC was not enhanced. Eight (62%) patients had a twofold or higher increase in mRNA transcript for IFN-γ, two (15%) patients had elevated serum levels of IFN-γ and 12 (92%) had increases angiogenic MIG and IP-10. In trastuzumab-refractory patients adding IL-2 did not produce responses and did not result in NK cell expansion. However, these patients had the ability to respond to IL-2 as evidenced by increases in IFN-γ transcripts and chemokines. The lack of NK cell expansion may explain the absence of clinical benefit.

KW - Breast cancer

KW - Clinical trial

KW - Her-2/neu

KW - Interleukin-2

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=69049096137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69049096137&partnerID=8YFLogxK

U2 - 10.1007/s10549-008-0251-7

DO - 10.1007/s10549-008-0251-7

M3 - Article

C2 - 19051009

AN - SCOPUS:69049096137

VL - 117

SP - 83

EP - 89

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -